RECURSION PHARMACEUTICALS, INC.RXRX
| Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
---|
Net loss | -186 | -239 | -328 |
---|
Depreciation and amortization | 8 | 12 | 24 |
---|
Stock-based compensation | 15 | 28 | 54 |
---|
Asset impairment | - | 3 | 1 |
---|
Lease expense | - | 8 | 8 |
---|
Loss on debt extinguishment | -1 | - | - |
---|
Other, net | -4 | -1 | -3 |
---|
Other receivables and assets | 5 | 0 | 8 |
---|
Unearned revenue | -10 | 110 | -41 |
---|
Accounts payable | 2 | 2 | -1 |
---|
Accrued development expense | 1 | 1 | 3 |
---|
Accrued expenses and other current liabilities | 13 | -1 | 7 |
---|
Operating lease liabilities | - | -7 | -10 |
---|
Net cash used in operating activities | -159 | -84 | -288 |
---|
Net loss | -186 | -239 | -328 |
---|
Depreciation and amortization | 8 | 12 | 24 |
---|
Stock-based compensation | 15 | 28 | 54 |
---|
Asset impairment | - | 3 | 1 |
---|
Lease expense | - | 8 | 8 |
---|
Loss on debt extinguishment | -1 | - | - |
---|
Other, net | -4 | -1 | -3 |
---|
Other receivables and assets | 5 | 0 | 8 |
---|
Unearned revenue | -10 | 110 | -41 |
---|
Accounts payable | 2 | 2 | -1 |
---|
Accrued development expense | 1 | 1 | 3 |
---|
Accrued expenses and other current liabilities | 13 | -1 | 7 |
---|
Operating lease liabilities | - | -7 | -10 |
---|
Net cash used in operating activities | -159 | -84 | -288 |
---|
Purchases of property and equipment | 40 | 37 | 12 |
---|
Net cash and restricted cash acquired in the acquisition of a business | - | - | -2 |
---|
Net cash and restricted cash acquired in the acquisition of a business | - | - | -2 |
---|
Purchases of property and equipment | 40 | 37 | 12 |
---|
Purchase of an intangible asset | - | 0 | 1 |
---|
Purchases of investments | 301 | - | - |
---|
Sales and maturities of investments | 69 | 231 | 0 |
---|
Net cash provided by (used in) investing activities | -272 | 193 | -10 |
---|
Net cash provided by (used in) investing activities | -272 | 193 | -10 |
---|
Proceeds from Issuance of Common Stock | - | 144 | 128 |
---|
Proceeds from Issuance Initial Public Offering | 463 | - | - |
---|
Proceeds from equity incentive plans and warrants | 8 | 11 | 13 |
---|
Repayment of long-term debt | 13 | 0 | 1 |
---|
Proceeds from equity incentive plans and warrants | 8 | 11 | 13 |
---|
Net cash provided by financing activities | 459 | 154 | 140 |
---|
Repayment of long-term debt | 13 | 0 | 1 |
---|
Net cash provided by financing activities | 459 | 154 | 140 |
---|
Effect of exchange rate changes on cash, cash equivalents and restricted cash | - | -0 | 0 |
---|
Net change in cash, cash equivalents and restricted cash | 28 | 264 | -158 |
---|
Conversion of Stock, Amount Converted | 448 | - | - |
---|
Stock Issued | - | - | 22 |
---|
Right-of-use asset additions and modifications | - | 4 | 5 |
---|
Accrued property and equipment | 8 | 1 | 2 |
---|
Right-of-use asset additions and modifications | - | 4 | 5 |
---|
Conversion of Stock, Amount Converted | 448 | - | - |
---|
Stock Issuance Costs, Noncash | 1 | - | - |
---|
Cash paid for interest | 1 | 0 | 0 |
---|
Cash paid for operating leases | - | 7 | 10 |
---|
Cash paid for operating leases | - | 7 | 10 |
---|
Cash paid for interest | 1 | 0 | 0 |
---|
Purchases of property and equipment | 40 | 37 | 12 |
---|
Net cash and restricted cash acquired in the acquisition of a business | - | - | -2 |
---|
Net cash and restricted cash acquired in the acquisition of a business | - | - | -2 |
---|
Purchases of property and equipment | 40 | 37 | 12 |
---|
Purchase of an intangible asset | - | 0 | 1 |
---|
Purchases of investments | 301 | - | - |
---|
Sales and maturities of investments | 69 | 231 | 0 |
---|
Net cash provided by (used in) investing activities | -272 | 193 | -10 |
---|
Net cash provided by (used in) investing activities | -272 | 193 | -10 |
---|
Proceeds from Issuance of Common Stock | - | 144 | 128 |
---|
Proceeds from Issuance Initial Public Offering | 463 | - | - |
---|
Proceeds from equity incentive plans and warrants | 8 | 11 | 13 |
---|
Repayment of long-term debt | 13 | 0 | 1 |
---|
Proceeds from equity incentive plans and warrants | 8 | 11 | 13 |
---|
Net cash provided by financing activities | 459 | 154 | 140 |
---|
Repayment of long-term debt | 13 | 0 | 1 |
---|
Net cash provided by financing activities | 459 | 154 | 140 |
---|
Effect of exchange rate changes on cash, cash equivalents and restricted cash | - | -0 | 0 |
---|
Net change in cash, cash equivalents and restricted cash | 28 | 264 | -158 |
---|
Conversion of Stock, Amount Converted | 448 | - | - |
---|
Stock Issued | - | - | 22 |
---|
Right-of-use asset additions and modifications | - | 4 | 5 |
---|
Accrued property and equipment | 8 | 1 | 2 |
---|
Right-of-use asset additions and modifications | - | 4 | 5 |
---|
Conversion of Stock, Amount Converted | 448 | - | - |
---|
Stock Issuance Costs, Noncash | 1 | - | - |
---|
Cash paid for interest | 1 | 0 | 0 |
---|
Cash paid for operating leases | - | 7 | 10 |
---|
Cash paid for operating leases | - | 7 | 10 |
---|
Cash paid for interest | 1 | 0 | 0 |
---|